Laboratory Corporation of America Holdings
NYSE:LH
Intrinsic Value
The intrinsic value of one
LH
stock under the Base Case scenario is
291.8
USD.
Compared to the current market price of 218.41 USD,
Laboratory Corporation of America Holdings
is
Undervalued by 25%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
LH Profitability Score
Profitability Due Diligence
Laboratory Corporation of America Holdings's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Laboratory Corporation of America Holdings's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
LH Solvency Score
Solvency Due Diligence
Laboratory Corporation of America Holdings's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Laboratory Corporation of America Holdings's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Laboratory Corporation of America Holdings
| Current Assets | 4.6B |
| Cash & Short-Term Investments | 430M |
| Receivables | 3B |
| Other Current Assets | 1.2B |
| Non-Current Assets | 15.5B |
| Long-Term Investments | 65.7M |
| PP&E | 3B |
| Intangibles | 12.1B |
| Other Non-Current Assets | 440M |
| Current Liabilities | 3.1B |
| Accounts Payable | 935M |
| Accrued Liabilities | 1.3B |
| Other Current Liabilities | 889M |
| Non-Current Liabilities | 7B |
| Long-Term Debt | 5.1B |
| Other Non-Current Liabilities | 1.9B |
LH Capital Structure
Laboratory Corporation of America Holdings
| Market Capitalization | 19.3B USD | |
| Total Debt | 5.1B USD | |
| Minority Interest | 18.9M USD | |
| Preferred Equity | 0 USD | |
| Cash and Equivalents | 430M USD | |
| Short-Term Investments | 0 USD | |
| Enterprise Value | 24B USD | |
Wall St
Price Targets
LH Price Targets Summary
Laboratory Corporation of America Holdings
According to Wall Street analysts, the average 1-year price target for
LH
is 292.49 USD
with a low forecast of 262.6 USD and a high forecast of 319.2 USD.
Ownership
LH Insider Trading
Buy and sell transactions by insiders
During the last 12 months Laboratory Corporation of America Holdings insiders bought 20.3k USD , and sold 17.7M USD worth of shares. The last transaction was made on Mar 25, 2023 by Kirchgraber Paul R (CEO, Covance Drug Development), who sold 2M USD worth of LH shares.
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
2.4M
USD
|
N/A
|
-2.4M
|
| 6 Months |
7.9M
USD
|
N/A
|
-7.9M
|
| 9 Months |
16.2M
USD
|
10.2k
USD
|
-16.2M
|
| 12 Months |
17.6M
USD
|
20.3k
USD
|
-17.5M
|
Shareholder Return
LH Return Decomposition
Main factors of price return
Market capitalization of
LH
shares
increased
by
15.3%
over the past 5 years.
The primary factor behind the change was
an increase
in revenue growth from
10.7B
to
14.9B, leading to a
growth
in the market capitalization of Laboratory Corporation of America Holdings by 34.99%.
Market capitalization of
LH
shares
increased
by
15.3%
over the past 5 years.
The primary factor behind the change was
an increase
in revenue growth from
10.7B
to
14.9B, leading to a
growth
in the market capitalization of Laboratory Corporation of America Holdings by 34.99%.
LH Price
Laboratory Corporation of America Holdings
| Average Annual Return | 19.27% |
| Standard Deviation of Annual Returns | 29.9% |
| Max Drawdown | -47% |
| Market Capitalization | 19.3B USD |
| Shares Outstanding | 89 000 000 |
| Percentage of Shares Shorted | 2.28% |
Company Profile
Laboratory Corporation of America Holdings
Country
Industry
Market Cap
Dividend Yield
Description
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. The company is headquartered in Burlington, North Carolina and currently employs 75,500 full-time employees. The Company’s business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The firm also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The firm serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers. The company also helps in delivering non-clinical testing services.
Contact
IPO
Employees
Officers
The intrinsic value of one
LH
stock under the Base Case scenario is
291.8
USD.
Compared to the current market price of 218.41 USD,
Laboratory Corporation of America Holdings
is
Undervalued by 25%.
